Registry for Esophageal and Gastroesophageal Junction Cancer

Inclusion Criteria

• •Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:
• •Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)
• •Liver
• •Lung
• •Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)
• •Adrenal gland
• •Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease \[positive cytology\])
• •Bone
• •≤2 sites of disease (excluding the primary tumor and regional lymph nodes)
• •≤3 tumors within each organ system
• •≤5 metastases
• •All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion
• •Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites
• •All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:
• •Surgery
• •Definitive chemoradiation
• •Stereotactic radiation
• •Ablation or similar techniques (e.g., irreversible electroporation)
• •Age ≥18 years